Colorectal Cancer Clinical Trials in New York

Showing 201-220 of 332 trials

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577

The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.

Kidney CancerHead and Neck CancerBreast Cancer+6 more

Weill Medical College of Cornell University20 participantsStarted Jul 2009

New York, New York, United States

COMPLETEDNA< 1 mile

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

NCT04708951

The study is intended to compare the detection rate obtained by performing G-EYE® high definition colonoscopy vs. the detection rate obtained by performing ECV high definition colonoscopy.

AdenomaColorectal Cancer

Dr. Horst Schmidt Klinik GmbH970 participantsStarted Jan 2021

Indianapolis, Indiana, United States • New York, New York, United States • Wiesbaden, Germany

COMPLETEDPhase 1< 1 mile

Preoperative Radiotherapy and E7046 in Rectum Cancer

NCT03152370

This is a multicenter, open-label, Phase 1b study in participants with locally advanced rectum cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by magnetic resonance imaging (MRI). It is conducted to assess the safety, to assess the tolerability, and to determine the recommended Phase 2 dose (RP2D) of E7046 in combination with pre-operative chemoradiotherapy. The study will also assess the efficacy of the combination in the expansion part at RP2D.

Neoadjuvant Therapy in Rectal Cancer

Adlai Nortye Biopharma Co., Ltd.29 participantsStarted May 2017

Boston, Massachusetts, United States • New York, New York, United States • Warsaw, Poland +2 more locations

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

Preoperative Radiotherapy and E7046 in Rectum Cancer

Colorectal Cancer Trials in Other Cities

Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Tissue and Serum Collection From Colorectal Cancer Patients

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Longitudinal Performance of Epi proColon

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Other Conditions in New York